Publications by Dr Yvette Drew - ePrints

Browsing publications by Dr Yvette Drew.

Newcastle Authors	Title	Year
Dr Yvette Drew Professor Ruth Plummer	Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study	2024
Dr Ann Fisher Dr Yvette Drew Dr Rachel O'Donnell	Enteric Type Bartholin Gland Adenocarcinoma: An Unusual Variant of a Rare Neoplasm	2021
Dr Sweta Sharma Saha Lucy Gentles Dominik Brecht Dr Rachel O'Donnell Professor Nicola Curtin et al.	Genomic, transcriptomic, and functional alterations in DNA damage response pathways as putative biomarkers of chemotherapy response in ovarian cancer	2021
Lucy Gentles Professor Nicola Curtin Dr Yvette Drew Dr Rachel O'Donnell	Integration of computer-aided automated analysis algorithms in the development and validation of immunohistochemistry biomarkers in ovarian cancer	2021
Alice Bradbury Dr Rachel O'Donnell Dr Yvette Drew Professor Nicola Curtin Dr Sweta Sharma Saha et al.	Characterisation of ovarian cancer cell line NIH-OVCAR3 and implications of genomic, transcriptomic, proteomic and functional DNA damage response biomarkers for therapeutic targeting	2020
Dr Nicola Cresti Dr Yvette Drew	First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor	2020
Dr Yvette Drew	Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non- BRCA1/2-Mutant Cancers	2020
Alice Bradbury Sally Hall Professor Nicola Curtin Dr Yvette Drew	Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?	2020
Dr Yvette Drew	Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer	2020
Dr Asima Mukhopadhyay Dr Yvette Drew Liz Matheson Dr Mo Salehan Lucy Gentles et al.	Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors	2019
Lucy Gentles Bojidar Goranov Elizabeth Matheson Dr Ashleigh Herriott Dr Angelika Kaufmann et al.	Exploring the frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types	2019
Professor Nicola Curtin Dr Yvette Drew Dr Sweta Sharma Saha	Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy	2019
Dr Yvette Drew	An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in gremlin BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)	2018
Lucy Gentles Liz Matheson Dr Nicholas Bown Alice Bradbury Maryam Zanjirband Zanjirband et al.	Characterization and drug sensitivity of a novel human overian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor	2018
Dr Sarah Fordham Dr Helen Blair Dr Claire Elstob Professor Ruth Plummer Dr Yvette Drew et al.	Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase	2018
Dr Yvette Drew	A phase I-II study of the oral PARP inhibitor Rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumours	2017
Dr Miranda Patterson Dr Yvette Drew Professor Nicola Curtin	PARP	2017
Dr Stuart Rundle Alice Bradbury Dr Yvette Drew Professor Nicola Curtin	Targeting the ATR-CHK1 Axis in Cancer Therapy	2017
Dr David Jamieson Melanie Griffin Julieann Sludden Dr Yvette Drew Dr Nicola Cresti et al.	A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours	2016
Dr Yvette Drew	Homologous recombination deficiency and ovarian cancer	2016
Dr Ganiy Abdulrahman Elizabeth Matheson Dr Yvette Drew Professor Nicola Curtin Dr Asima Mukhopadhyay et al.	Investigating PARP inhibitor sensitisation by hyperthermia and HSP90 inhibition	2016
Dr Yvette Drew Dr Martin Highley Julieann Sludden Dr James Murray Dr David Jamieson et al.	Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer	2016
Elizabeth Matheson Dr Mo Salehan Dr Asima Mukhopadhyay Professor Nicola Curtin Dr Yvette Drew et al.	Preclinical studies of the PARP inhibitor olaparib in combination with imatinib in BRCA stratified ovarian cancer	2016
Dr Yvette Drew Professor Alastair Greystoke Professor Ruth Plummer	A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM).	2015
Dr Yvette Drew	A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation	2015
Dr Yvette Drew	A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation	2015
Dr Yvette Drew	The development of PARP inhibitors in ovarian cancer: from bench to bedside	2015
Professor Ruth Plummer Dr Nicola Cresti Dr Yvette Drew Dr Peter Stephens Dr Jared Thornton et al.	Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma	2014
Dr Yvette Drew Ajay Gupta Professor Ruth Plummer	A Phase 1 Study of Oral or Intravenous Rucaparib in Combination in Combination with Platinum-Containing Chemotherapeutic Regimens: Analysis of Patients with Ovarian or Peritoneal Tumors	2013
Dr Nicola Cresti Dr Yvette Drew Professor Ruth Plummer	A phase I study of oral rucaparib in combination with carboplatin	2013
Bojidar Goranov Dr Yvette Drew Jonathon Graham Dr Rachel Pearson	Academic opportunities within clinical oncology training	2013
Dr Jane Margetts Dr Yvette Drew Dr Peter Stephens Professor Alan Calvert Professor Ruth Plummer et al.	Erratum to: Phase I study of PM00104 (Zalypsis (R)) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors (vol 31, pg 623, 2013 Doi: 10.1007/s10637-012-9843-5)	2013
Dr Jane Margetts Dr Yvette Drew Professor Ruth Plummer	Phase I study of PM00104 (Zalypsis (R)) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors	2013
Dr Yvette Drew Dr Evan Mulligan Wan Vong Huw Thomas Suzanne Kyle et al.	Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2	2011
Rachel Daniel Dr Agata Rozanska Dr Evan Mulligan Dr Yvette Drew Huw Thomas et al.	Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699	2010
Dr Asima Mukhopadhyay Dr Ahmed Elattar Dr Aiste McCormick Sarah Wilkinson Dr Yvette Drew et al.	Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors	2010
Dr Yvette Drew Professor Ruth Plummer	The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer	2010
Dr Evan Mulligan Tomasz Zaremba Dr Yvette Drew Professor Ruth Plummer Professor Nicola Curtin et al.	[abstract] Validated sensitive immunological determination of PARP-1 protein levels and activity in cultured cells and human lymphocytes	2009
Dr Agata Rozanska Huw Thomas Dr Evan Mulligan Dr Yvette Drew Deborah Castelbuono et al.	Inhibition of Poly (ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma	2009
Dr Yvette Drew Professor Ruth Plummer	PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications	2009
Dr Yvette Drew Suzanne Kyle Professor Richard Edmondson Professor Ruth Plummer Professor Nicola Curtin et al.	Investigating DNA double strand break formation and repair in response to the PARP inhibitor AG014699 in cell lines defective in Homologous Recombination: a role for PARP inhibitors in sporadic cancers? [abstract]	2008
Professor Alan Calvert Professor Ruth Plummer Professor Nicola Curtin Professor Richard Edmondson Dr Yvette Drew et al.	PARP inhibitors in cancer treatment	2008
Dr Yvette Drew Professor Alan Calvert	The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers	2008
Dr Yvette Drew Professor Alan Calvert	The potential of PARP inhibitors in genetic breast and ovarian cancers	2008